abstract |
The present invention relates to pharmaceutical agents administered to a subject either in combination or in series, for the treatment of a viral infection by flaviviridae, for example, hepatitis C virus (HCV), wherein the treatment comprises administering a compound effective to inhibit the function of the hepatitis C virus NS5A protein (HCV), and an additional compound or combinations of additional compounds that have activity against hepatitis O virus (anti-HCV). |